



    ISSN - 0975-7058 
Vol 11, Special Issue 6, 2019 




KUSMARDI KUSMARDI1, VANNESSA KARENINA2*, ARI ESTUNINGTYAS3, ARYO TEDJO4 
1Department of Pathological Anatomy, Faculty of Medicine, Universitas Indonesia, Indonesia, 2Undergraduate Student, Faculty of 
Medicine, Universitas Indonesia, Indonesia, 3Department of Pharmacology and Therapeutic, Faculty of Medicine, Universitas Indonesia, 
Indonesia, 4
Received: 12 Dec 2018, Revised and Accepted: 10 Mar 2019 
Department of Medical Chemistry, Faculty of Medicine, Universitas Indonesia, Indonesia 
Email: vannessa.karenina@ui.ac.id 
ABSTRACT 
Objective: The incidence of colorectal cancer has been growing faster than most other cancers in the past decade, especially in developing 
countries. One of the substances that is currently being investigated as potential chemopreventive agent is lunasin, which is contained in soybeans. 
This research explored the effect of lunasin on COX-2 expression in the distal colons of mice in which colorectal carcinogenesis was induced with 
azoxymethane (AOM) and dextran sodium sulfate (DSS).  
Methods: A total of 30 Swiss Webster mice were separated into six groups. In five of the groups—a negative control group, positive control group, 
and three intervention groups—carcinogenesis was induced with AOM and DSS; the sixth group received no interventions. Lunasin-rich soybean 
extracts were given in doses of 250, 300, and 350 mg/kgBW for 6 w to the intervention groups.
Results: Significant differences between the negative control and the intervention groups were found at the 300 mg/kgBW (p = 0.047) and 350 
mg/kgBW (p = 0.016) lunasin dosage levels. 
 Immunohistochemical staining of COX-2 was then 
carried out on tissue samples from the distal colons of mice that had been sacrificed. The samples were microscopically assessed and photographed, 
and cell counts were performed using the Image J application. COX-2 expression is reported in the form of an optical density score (ODS). 
Conclusions: This demonstrates that administration of lunasin-rich soy extracts can inhibit COX-2 expression in cryptic epithelial cells of the distal 
colon in mice with carcinogenesis induced by AOM and DSS. 
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INTRODUCTION 
Colorectal cancer is the third most common cancer in men (746,000 
cases) and the second in women (614,000 cases) worldwide [1]. 
Although 55% of colorectal cancer events occur in developed 
countries, the most rapid increases in the incidence of colorectal 
cancer are estimated to be occurring in developing countries. This is 
due to changes in lifestyle and eating patterns that are increasingly 
widespread, such as obesity, lack of physical activity, smoking, lack 
of consumption of fibrous foods, and increased consumption of 
alcohol [2]. 
Conventional treatments of colorectal cancer such as surgery, 
radiation therapy, chemotherapy, and immunotherapy have not 
been able to give desirable results. Surgical management is reported 
to have a risk of post-operative complications. Radiation therapy is 
reported to have a risk of increasing colorectal cancer recurrence [3, 
4]. Chemotherapy, which works by damaging cancer cells, is also 
reported to damage healthy cells if given for a long time [5]. 
Currently, nutritional therapy is being intensively studied for the 
treatment of colorectal cancer. The goal of this therapy is to prevent 
cancer and inhibit cancer progression. Soybeans are 
epidemiologically proven to be beneficial to health, especially in 
reducing the risk of cardiovascular and cancer diseases [6]. Several 
studies show that the consumption of soybeans can suppress tumor 
growth in various tissues, such as the skin, mammary glands, 
bladder, and prostate [7]. 
The active substance in soybeans that has the potential to become a 
chemopreventive agent is lunasin. Lunasin is a polypeptide, composed 
of 43 amino acids, that has antioxidant, antihypertensive, anti-
inflammatory and anticancer effects. Lunasin contains eight negatively 
charged Asp (D) residues on the carboxyl end, which provide a histone 
binding site that allows it to act as a potent inhibitor of the positively 
charged histone acetylations H3 and H4. In addition, the Arg-Gly-Asp 
(RGD) motive in lunasin also plays a role in its internalization into 
mammalian cells. This RGD motive can induce cell apoptosis through 
caspase mechanisms that are associated with cell growth and 
proliferation, maintenance of cell function, and cell interaction [8, 9]. In 
addition, there is a putative helical region in lunasin which is thought 
to increase its ability to bind to chromatin [10]. 
Studies on tumors treated with lunasin also showed a significant 
decrease in cell proliferation accompanied by tumor cell apoptosis 
induction.[8] Histologic staining in samples of tumors treated with 
lunasin showed that the destructive area of the tumor was replaced by 
necrotic and apoptotic cells [9]. Pure lunasin isolated from Bowman-
Birk inhibitor (BBI) concentrates can reduce focus formation by 73% 
at a concentration of 100 nM. BBI is a protease inhibitor in soybeans 
that can increase the bioavailability of lunasin [10]. 
The degree of COX-2 expression is a parameter that can be used to 
see the effect of lunasin on colorectal carcinogenesis. The COX-2 
enzyme is found in some normal cells, but it is mainly induced by an 
inflammatory response or cancer stimulus. An increase in COX-2 
expression is found in most colorectal cancers. The role of COX-2 in 
producing prostaglandins from arachidonic acid is also known to 
play an important role in cancer progression through angiogenesis 
and the increase of cell proliferation [11]. 
Through an investigation of soybeans, a food that is easily found in 
Indonesia at affordable prices and with no toxic effects, this study 
was designed to analyze the effect of lunasin extracted from 
soybeans on distal colon tissue in mice in which colorectal 
carcinogenesis was induced using azoxymethane (AOM) and dextran 
sodium sulfate (DSS). 
MATERIALS AND METHODS  
This study was designed as an experimental study using primary 
data in the form of quantification of COX-2 expression. The 
expression of COX-2 was observed in immunohistochemically 
stained preparations of distal colon tissue from mice that had been 
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sacrificed, specifically the cryptic epithelium cells. The preparations 
were obtained from stored tissue. Observations of the preparation 
was carried out using a microscope at 400 times magnification in 
five fields of view. This study was conducted at the Anatomy 
Pathology Laboratory of the Faculty of Medicine at Universitas 
Indonesia in Salemba, Jakarta, from January 2018 to October 2018. 
Plant materials and extraction procedures 
The soybeans used in this research were a Grobogan variety. These 
soybeans were obtained from the Indonesian Legumes and Tuber 
Crops Research Institute in Malang, East Java. Before lunasin 
extraction was carried out, the soybeans underwent a pressing 
process to remove their oil at the Herbs and Medicinal Plants 
Research Institute in Bogor, West Java. Following the pressing 
process, the dried soybeans were then blended into powder. 
This soybean powder (1,250 g) was then macerated for 60 min using 
a phosphate buffer saline solvent, using 5 times as much solvent as 
soybean powder (6,250 ml) [12, 13]. Afterwards, the maceration 
solution was filtered 3 times with filter gauze, and the resulting 
extract solution was dried at 50°C using an evaporator. 
Analysis of the lunasin content of each extract was carried out using 
high-performance liquid chromatography. The extract was diluted with 
distilled water and centrifuged at 12,000 rpm for 30 min. The resulting 
solution was first filtered through a 0.22 m membrane, then injected into 
a high performance liquid chromatography (HPLC) device equipped with 
a UV-Vis detector L-2420 (295 nm) in the car phase (5% acetonitrile and 
95% distilled water). The analysis was carried out with a linear gradient 
for 35 min at a speed of 2 ml/minute. The lunasin level was identified 
based on retention time using the lunasin standard. 
Animals 
Male Swiss Webster mice (12 w old), approximately 250 grams, 
were obtained from the Agency for Health Research of the 
Development Ministry of Health of Republic of Indonesia. Mice were 
adapted for 1 w at the Anatomy Pathology Laboratory of the Faculty 
of Medicine at Universitas Indonesia. Mice were maintained and 
treated at a controlled temperature (25°C), humidity (55%), light-
dark cycle (12 h), and were given standard food and drink according 
to the Guide for the Care and Use of Laboratory Animals from the 
Animal Care and Use Committee in United States, which applied 
universally. The physical health of the mice, including their levels of 
activity, consumption of food and drink, and weight, were examined. 
Induction of carcinogenesis 
The process of inducing colorectal carcinogenesis in mice was adopted 
from Kusmardi et al. [14], where mice given azoxymethane (AOM) 
dissolved in 0.9% NaCl through intraperitoneal (IP) injection in a 
single dose of 10 mg/kgBW at the beginning of the trial week. A week 
after the administration of AOM, mice were given food and drink 
containing 2% dextran sodium sulfate (DSS) every day for a week. 
Treatments in experimental groups 
The mice were divided into six experimental groups: the normal 
group, a positive control group, a negative control group, and three 
intervention groups. The normal group (N) represents the normal 
condition of the mice before the carcinogenesis. This group was not 
given AOM and DSS, but instead received IP injections of 
physiological saline for 4 w. The negative control group (KN) 
represents the condition of the mice after carcinogenesis, without 
any subsequent treatment. This group was given a single dose of AOM 
via IP injection followed by oral DSS for a week, then given 
physiological saline for 4 w. The positive control group (KP) 
represents the results of the most widely used treatment for inhibiting 
carcinogenesis. The mice in this group were given a single dose of AOM 
via IP injection followed by oral DSS for a week, then treated with oral 
aspirin (150 mg/kgBW) for 4 w. The lunasin therapy groups (L1, L2, 
L3) represent the results of the proposed treatments in inhibiting 
carcinogenesis. The mice in these groups were given a single dose of 
AOM via IP injection followed by oral DSS for a week, then 
administered lunasin-rich soybean extract orally (L1: 250 mg/kgBW; 
L2: 300 mg/kgBW; and L3: 350 mg/kgBW) for 4 w (fig. 1). 
 
 
Fig. 1: Scheme of treatments in experimental groups 
 
The minimum sample amount was calculated based on Federer's 
formula, 
(n-1) (k-1) ≥ 15, 
With n = the number of samples in each group and k = the number of 
experimental groups. 
(n-1) (6-1) ≥ 15 
n-1 ≥ 3 
n ≥ 4 
Based on the calculation above, the minimum number of samples in 
each experimental group was 4 mice, or 24 mice in total. This study, 
however, used 30 mice, or 5 per experimental group. 
Immunohistochemistry staining 
At the end of the treatment period, each mouse was anesthetized 
with IP injections of ketamine and xylazine, then terminated using 
the neck dislocation technique. Colon tissue samples obtained from 
the mice were made into preparations in paraffin blocks and cut 
across in 4 µm thick slices. Specimens were incubated with suitable 
secondary antibodies for 1 hour at room temperature. The 
incubation of the specimens was then carried out again with 
trekavidin conjugated with HRP for the next 30 min. Proteins were 
visualized using 3,3'-diaminobenzidine (DAB) for 10 min at room 
temperature. After that, each specimen was dipped into Lilie Mayer 
hematoxylin dye as a counterstain for 1–2 min, then rinsed with 
running water. The tissue was then dipped in lithium carbonate for 1 
minute and rinsed with running water. Finally, they were dehydrated 
with ethanol and purified with xylol. These steps end with the closure 
of the specimen with aqueous mounting media. Positive control of 
immunohistochemical staining is liver cancer cells. 
Assessment of COX-2 expression 
COX-2 expression in the cytoplasm of colonic crystalline epithelial 
cells was assessed semiquantitatively. The bluish-colored epithelium 
indicates a negative result, while the brown epithelium indicates 
positive results. Assessment of COX-2 immunohistochemistry results 
was performed via a double-blind procedure. All slides were 
observed with a light microscope. Photos were taken at 400x 
magnification in five random fields of view. 
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Based on the color intensity, cryptic epithelial cells were divided into 
four groups: high positive cells, moderate positive cells, low positive 
cells and negative cells. High positive cells were defined as cells that 
contain dark brown pigments coloring all of the cytoplasm. 
Moderate positive cells were defined as cells that contain lighter 
brown pigments coloring all of the cytoplasm. Low positive cells 
were defined as cells that contain lighter brown pigments coloring 
half of the clear cytoplasms. Negative cells were defined as cells that 
contain slight or no brown pigments marked by cytoplasm that 
appear clear or bluish (fig. 2). 
  
 
Fig. 2: Standard for determining color intensity in preparations In this figure, A–D illustrate the following: A) high positive cells, B) 
moderate positive cells, C) low positive cells, D) negative cells 
 
The total number of positive and negative cells in each photo was 
calculated manually by marking the cryptic epithelial cells using the 
Image J application. Based on the intensity of the color, positive 
results were next categorized as high positive, marked with a dark 
blue dot; moderate positive, marked with a light blue dot; and low 
positive, marked with a light green dot. Negative results are marked 
with a purple dot. The interpretation results were quantified as 
optical density scores (ODS) and expressed in percentages. 
Management and analysis of data 
Statistical analysis of this study used SPSS for Mac, version 24.0. 
Because the number of samples was less than 50, we performed the 
Shapiro-Wilk normality test. Furthermore, the Levene test was 
conducted to determine the homogeneity of the variance of the data.  
If the data had a normal distribution and homogenous variance, 
parametric variance analysis (ANOVA) was carried out to find out 
whether there was a significant difference between groups. ANOVA 
tests were used because the number of groups being compared was 
more than two. If there was a significant difference, the two mean 
analyses were done via a post hoc test to find out which groups had 
significant differences. 
If the data were abnormally distributed, or if they were normally 
distributed but the variance was not homogeneous, a Kruskal-Wallis 
nonparametric test was used to determine the presence of 
significant differences between groups. If a significant difference 
was found, the Mann Whitney nonparametric test was conducted to 
identify which groups had significant differences. 
RESULTS  
The effect of lunasin-rich soybean extract on COX-2 expression in the 
cryptic epithelial cells of the distal colon tissue in mice that had 
colorectal carcinogenesis induced via administration of AOM and DSS 
is shown in table 1. The highest COX-2 expression was found in the 
negative control group, while the lowest expression was found in the 
positive control group. The decrease of COX-2 expression in the groups 
given lunasin-rich soybean extract was found to be dose-dependent.
 
Table 1: Descriptive analysis of COX-2 expression in the control groups and lunasin therapy groups 
Groups Median (Min–Max) 
Normal 234.95 (228.42–264.50) 
Negative control 293.38 (276.06–375.48) 
Positive control 259.83 (246.85–268.96) 
Lunasin 250 280.31 (270.47–301.04) 
Lunasin 300 269.18 (267.79–297.19) 
Lunasin 350 261.96 (247.68–277.56) 
 
The Shapiro Wilk normality test showed that the data was not 
normally distributed (p = 0.003). Data transformation with the log 
function was performed to normalize the data, but the results of 
normality tests show that the data was still not normally distributed. 
Furthermore, the Levene homogeneity test indicated that the 
variance of the data was not homogeneous (p = 0.028). Because the 
data obtained were not normally distributed and not homogeneous, 
the analysis was continued with a Kruskal-Wallis nonparametric 
test, which determined that there were significant differences 
between groups (p = 0.001). 
To find out which groups had significant differences, the Mann 
Whitney test was used, and showed that there were significant 
differences between many of the groups, in particular: the N group 
with KN group (p = 0.009); the L1 group (p = 0.009) and L2 group (p 
= 0.009); the KN group with the KP group (0.009); the L2 group (p = 
0.047) and L3 group (p = 0.016); the KP group with the L1 group (p 
= 0.009) and L2 group (p = 0.016) (fig. 3). 
The comparison of the immunohistochemical staining results of 
COX-2 expression between the control groups and intervention 
groups can be seen in fig. 4. Higher-intensity brown colors in 
epithelial cells show higher positive results produced by COX-2 
expression in these cells. In the N group, most epithelial cells were 
clear/bluish (negative) or faint brown (low positive). In the KN 
group, higher intensities of brown were observed in most epithelial 
cells. In the KP group, low–medium intensity browns were the most 
common (low–medium positive). Meanwhile, in the lunasin 
intervention groups, there was a gradual decrease in brown color 
intensity as dosage increased. 
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Fig. 3: Graph of descriptive analysis of COX-2 expression in the control groups and lunasin therapy group 
 
 
Fig. 4: Immunohistochemical staining results of COX-2 expression in each treatment group, In this fig. A–F illustrate the following: A) 
normal, B) negative control, C) positive control, D) lunasin dose 250 mg/kgBW, E) lunasin dose 300 mg/kgBW, F) lunasin dose 350 
mg/kgBW 
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Based on the statistical tests that were carried out, it became clear 
that lunasin-rich soybean extract had a significant effect on COX-2 
expression at doses of 300 mg/kgBW (p = 0.047) and 350 mg/kgBW 
(p = 0.016). These findings are in line with the findings of Liu et al. 
[8] regarding the role of lunasin as an anti-inflammatory and 
anticancer agent. As an anti-inflammatory, lunasin plays an 
important role in inhibiting pro-inflammatory cytokines, such as 
TNF-and IL-6, without damaging cell viability. Dia et al. [15] showed 
that lunasin can also reduce iNOS and COX-2 expression, thereby 
reducing NO and PGE2 production. 
The use of the term lunasin-rich soybean extract in this study was 
intended to show that soybeans are a rich source of lunasin. Liu et al. 
[8] showed that soybeans are the food sources with the highest 
lunasin content, with a range of 0.5–8.1 mg/g. The result of the HPLC 
analysis showed that the lunasin content of the soybean extract used 
in this study was 0.823 mg/g. 
The dosages of lunasin-rich soybean extract in this study—250, 300, 
and 350 mg/kgBW—were determined based on previous work by 
Amalia et al. [16], which also used soybean extract in doses of 150 
mg/kgBW and 200 mg/kgBW. This study’s dose difference of 50 
mg/kgBW between the intervention groups was determined 
according to the previous study. 
Although there were no significant differences between the lunasin 
intervention groups (L1, L2 and L3), the results showed a gradual 
decrease in COX-2 expression at doses of 300 and 350 mg/kgBW 
compared to KN group. Therefore, inhibition of COX-2 expression 
can be said to be dose-dependent: higher doses of lunasin will result 
in greater inhibition of COX-2. These findings are in line with those 
of Dia et al. [15], which showed that increasing the dose of lunasin 
from 100 M to 200 M and then 300 M resulted in greater inhibition 
of COX-2 expression in HT-29 colorectal cancer cells. 
Factors that play an important role in the pathogenesis of colitis-
related colorectal cancer are the NF-B pathways, both in immune cells 
and epithelial cells, as well as activation of local cytokines and 
lymphokines. NF-B is a pro-inflammatory transcription factor that 
found in the cytoplasm in inactive form. Stimulus and extracellular 
signals in the form of inflammation will trigger a series of 
phosphorylation, ubiquitination, and degradation of NF-kB inhibitors 
that can activate NF-kB. When activated, NF-kB will translocate to the 
nucleus and trigger the transcription genes that encode cytokines, 
adhesion molecules, apoptotic regulators, cell cycle regulators, other 
transcription factors, and enzymes, including COX-2 [15]. 
According to Liu et al. [17], COX-2 expression is one of the factors 
that play an important role in the progression of colorectal cancer. 
This is because COX-2 mediates the formation of PGE2, which 
triggers the activation of the Wnt/β-catenin pathway; this, in turn, 
initiates a series of processes that lead to the abnormal proliferation 
of colon cells. 
An in vitro study conducted by Dia et al. [18] showed that the 
administration of lunasin can inhibit this proliferation and trigger 
apoptosis of HT-29 colorectal cancer cells. According to this study, 
the inhibition of cell proliferation due to lunasin occurred because 
cells are inhibited from entering the mitotic phase (G2/M), which is 
controlled by a regulator kinase called cyclin-dependent kinase 1 
(CDK1). 
In addition to proliferation inhibition, apoptosis induction is an 
anticancer mechanism that is induced by lunasin. The increase in 
apoptosis is characterized by the modification of B-cell lymphoma 2 
proteins (Bcl-2) and Bcl-2 associated X proteins (Bax). Supression of 
Bcl-2 protein expression that was anti-apoptotic and induction of 
Bax protein that was pro-apoptosis was found upon administration 
of lunasin [18] 
The significant differences between the KN and N groups indicate 
that the AOM and DSS given in the KN group were effective in 
inducing carcinogenesis through inflammatory pathways, including 
increasing COX-2 expression. The success of this induction of 
colorectal carcinogenesis is in line with the study by Rosenberg et al. 
[19] where administration of a single dose of AOM through IP 
injection followed by DSS in drinking water for a week showed the 
onset of tumors about 6 w after administration. Tanaka et al. [20] 
also showed that the administration of AOM and DSS using the same 
protocol caused distortion of the cryptic epithelium, irregular 
cryptic spread in lamina propria and infiltration of inflammatory 
cells about 3–4 w after administration. AOM and DSS were also 
known to cause severe colitis about 12 w after administration.  
The Mann Whitney test results also showed that there was a 
significant difference between the KP and KN groups (p = 0.009). 
This is in line with research conducted by Rothwell et al. [21] where 
long-term aspirin administration every day for 5 y is known to be 
useful in reducing the risk of death caused by all types of cancer. In 
addition, several cohort studies have also shown that the risk of 
death from colorectal cancer can decrease significantly (by 40%) 
after long-term aspirin treatment.[18] In this study, the use of 
aspirin at a dose of 150 mg/kgBW was based on a previous study by 
Amalia et al. [22] that analyzed the effect of soybean extract on 
apoptosis and dysplasia in the colons of mice that had 
carcinogenesis induced with AOM and DSS.  
COX-2 is the main pharmacological target of aspirin as a 
chemopreventive agent. This is based on the finding that aspirin can 
only reduce the risk of colorectal cancer in individuals with 
increased COX-2 expression. This finding is also associated with a 
reduced risk of mortality [23]. In colonic mucosal tissue, COX-2 is 
more commonly found in tumor tissue, including epithelial, 
endothelial, stromal, and mononuclear cells. The impact of increased 
COX-2 expression on colorectal cancer is related to increased 
prostaglandin production which causes apoptotic inhibition, 
stimulation of tumor growth, and angiogenesis [24]. 
Most of the previous research on lunasin has been done in in vitro 
studies. The advantage of this study is the ability to analyze the 
effect of several different dosage levels of lunasin on colorectal 
cancer in mice in vivo. Possible visual bias due to manual 
observation and quantification of immunohistochemical staining 
results might be a disadvantage of this study. Nevertheless, the 
subjectivity can be minimized by using an optical density scoring 
system. 
CONCLUSION  
The administration of lunasin-rich soybean extract inhibited COX-2 
expression in cryptic epithelial cells of the distal colon in mice in 
which colorectal carcinogenesis was induced by AOM and DSS. A 
statistically significant decrease in COX-2 expression was found at 
doses of 300 and 350 mg/kgBW in a dose-dependent manner. For 
the further studies, the authors recommend a longer period of 
carcinogenesis induction to be carried out to determine the efficacy 
of lunasin in a more severe model of colorectal cancer. This 
recommendation is based on some studies which show that it takes 
about 20 w for AOM and DSS to induce mice to progress to colorectal 
carcinoma [21]. 
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